Skip to main content

Table 6 Correlations between the optimal thresholds of TILs and pCR in neoadjuvant treated TNBCs

From: Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

Variables

Univariate analysis

Multivariate analysis

OR

95% CI

P-value

OR

95% CI

P-value

ITILs (< 10% vs. ≥10%)

2.62

1.38–4.97

0.003*

1.97

0.98-3.98

0.06

STILs (< 20% vs. ≥20%)

2.87

1.51–5.47

0.001*

2.85

1.38-5.90

0.005*

Age(years) (< 50 vs. ≥50)

0.51

0.27–0.95

0.04*

0.70

0.33-1.45

0.33

Histological grade (2 vs. 3)

2.74

1.11–6.80

0.03*

1.02

0.34-3.10

0.97

Tumor size (cm) (≤2 vs. 2–5 vs. > 5)

1.30

0.74–2.29

0.37

1.12

0.58–2.14

0.74

Nodal status (positive vs. negative)

0.93

0.48–1.81

0.84

1.76

0.82–3.79

0.15

LVI (positive vs. negative)

0.06

0.01–0.26

0.0001*

0.05

0.01-0.25

0.0001*

Ki-67 index

2.47

1.17–5.24

0.02*

1.03

1.01-1.04

0.004*

NAC (Anthracycline + paclitaxel vs. paclitaxel + platinum)

0.83

0.37–1.87

0.65

0.99

0.49–2.00

0.97

  1. Abbreviations: pCR pathological complete response, TNBCs triple-negative breast cancers, sTILs stromal tumor-infiltrating lymphocytes, iTILs intratumoral tumor-infiltrating lymphocytes, LVI lymphovascular invasion, NAC neoadjuvant chemotherapy, OR odds ratio, 95% CI 95% confidence interval
  2. *The P value is significant